{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T22:52:58Z","timestamp":1791327178439,"version":"4.3.1"},"reference-count":0,"publisher":"Pasifika Medical Association Group","issue":"1643","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["NZMJ"],"abstract":"<jats:p>aim: The aim of this study was to evaluate long-term real-world outcomes of anti\u2013vascular endothelial growth factor (anti-VEGF) therapy for neovascular age-related macular degeneration (nAMD) at a regional New Zealand centre, with a primary focus on treatment duration and reasons for cessation.\nmethods: A retrospective cohort study was conducted at Palmerston North eye clinic, including all newly diagnosed eyes with nAMD initiating anti-VEGF therapy between November 2017 and August 2023. Demographic data, visual acuity, treatment duration and documented reasons for cessation were extracted from a prospectively maintained database and validated against electronic health records.\nresults: Among 527 eyes from 446 patients, 39.8% ceased treatment. The most common reasons were end-stage disease (44.8%), patient death (21.9%), logistical factors (17.6%) and injection intolerance (8.1%). Mean treatment duration was 421 days. Visual outcomes were favourable overall with 20.2% of eyes improving and 59.5% remaining stable. Better baseline visual acuity strongly predicted better final vision.\nconclusions: High early cessation due to end-stage disease suggests possible late presentation, underscoring the need for earlier detection and referral. Addressing logistical barriers and supporting adherence will be increasingly important as demand for anti-VEGF therapy grows with an ageing population.<\/jats:p>","DOI":"10.26635\/6965.7545","type":"journal-article","created":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T22:40:37Z","timestamp":1791326437000},"page":"24-31","source":"Crossref","is-referenced-by-count":0,"title":["Longer-term outcomes of intravitreal therapy for neovascular age-related macular degeneration at a peripheral centre (Palmerston North eye clinic)"],"prefix":"10.26635","volume":"139","author":[{"given":"Brandon","family":"Nunns","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aqeeda","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Ah-Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"11177","published-online":{"date-parts":[[2026,10,9]]},"container-title":["New Zealand Medical Journal"],"original-title":[],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T22:40:39Z","timestamp":1791326439000},"score":1,"resource":{"primary":{"URL":"https:\/\/nzmj.org.nz\/journal\/vol-139-no-1643\/longer-term-outcomes-of-intravitreal-therapy-for-neovascular-age-related-macular-degeneration-at-a-peripheral-centre-palmerston-"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,9]]},"references-count":0,"journal-issue":{"issue":"1643","published-online":{"date-parts":[[2026,10,9]]}},"URL":"https:\/\/doi.org\/10.26635\/6965.7545","relation":{},"ISSN":["1175-8716"],"issn-type":[{"value":"1175-8716","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,9]]}}}